Metformin sensitizes therapeutic agents and improves outcome in pre-clinical and clinical diffuse large B-cell lymphoma

BACKGROUND: The treatment of diffuse large B-cell lymphoma (DLBCL) is limited by the development of resistance to therapy, and there is a need to develop novel therapeutic strategies for relapsed and refractory aggressive lymphoma. Metformin is an oral agent for type 2 diabetes that has been shown t...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Cancer Metab
Prif Awduron: Singh, Anil R., Gu, Juan J., Zhang, Qunling, Torka, Pallawi, Sundaram, Suchitra, Mavis, Cory, Hernandez-Ilizaliturri, Francisco J.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BioMed Central 2020
Pynciau:
Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7336499/
https://ncbi.nlm.nih.gov/pubmed/32647571
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40170-020-00213-w
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg